Skip to content
Review

Iridoid Scaffolds as Multitarget Antidiabetic Agents: Chemistry, Biosynthesis, Mechanisms, Structure–Activity Relationship, and Molecular Targets in Type 2 Diabetes Therapy

Sep 2026 · ChemistrySelect · 0 citations · 105 references

Abstract

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by chronic hyperglycemia, impaired insulin signalling, and progressive metabolic dysfunction, posing a major global health challenge. Natural products remain valuable sources of bioactive scaffolds for antidiabetic drug discovery, with iridoids attracting considerable attention due to their structural diversity and broad pharmacological activities. This review summarizes advances in iridoid research over the past three decades (up to October 2025), focusing on their chemical architecture, biosynthetic features, structural modifications, and antidiabetic mechanisms relevant to T2DM. Iridoids possess a cyclopentanoid monoterpene core that undergoes diverse chemical transformations, such as glycosylation, oxidation, and esterification, yielding structurally diverse derivatives, including glycosylated iridoids and bis‐iridoids. Medicinal chemistry strategies have aimed to enhance bioavailability, metabolic stability, and structure–activity relationships (SARs) to improve therapeutic potential. Several naturally occurring iridoids, including catalpol, geniposide, loganin, and aucubin, exhibit significant antihyperglycaemic, insulin‐sensitizing, and pancreatic β‐cell‐protective effects in experimental models. Mechanistic studies indicate that iridoids modulate multiple pathways involved in glucose and lipid metabolism, inflammation, and oxidative stress, supporting their role as multitarget antidiabetic agents. Although promising experimental evidence exists, clinical validation remains limited. Overall, iridoids represent promising lead scaffolds for the development of next‐generation therapeutics for T2DM.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.